Mangoceuticals Past Earnings Performance
Past criteria checks 0/6
Mangoceuticals's earnings have been declining at an average annual rate of -361.1%, while the Consumer Retailing industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 8083.2% per year.
Key information
-361.1%
Earnings growth rate
-209.0%
EPS growth rate
Consumer Retailing Industry Growth | 10.9% |
Revenue growth rate | 8,083.2% |
Return on equity | -1,189.1% |
Net Margin | -1,259.4% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Mangoceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -9 | 9 | 0 |
30 Sep 23 | 0 | -7 | 7 | 0 |
30 Jun 23 | 0 | -6 | 6 | 0 |
31 Mar 23 | 0 | -5 | 4 | 0 |
31 Dec 22 | 0 | -2 | 2 | 0 |
Quality Earnings: MGRX is currently unprofitable.
Growing Profit Margin: MGRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MGRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MGRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGRX is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Retailing industry (14.4%).
Return on Equity
High ROE: MGRX has a negative Return on Equity (-1189.08%), as it is currently unprofitable.